New York, October 29, 2024 - PRISM MarketView - IceCure Medical Ltd. (NASDAQ: ICCM) announced that a significant number of public comments from stakeholders, including doctors, nurses, researchers, and breast cancer patients, have been posted ahead of an upcoming FDA Advisory Panel meeting. The panel, scheduled for November 7, 2024, will review and provide recommendations on the benefit-risk profile of IceCure’s ProSense® Cryoablation System for early-stage, low-risk breast cancer treatment as part of a De Novo marketing submission. Shares of IceCure are up 21% following the announcement, and the company is currently leading the PRISM Med Devices Index.
“We are highly encouraged by the large number of comments received for the Advisory Panel’s consideration regarding the role of ProSense® as a minimally-invasive treatment option for early-stage low-risk breast cancer patients. Key stakeholders, including breast cancer patients, have shared their first-hand experience with ProSense®. We look forward to the public forum on November 7, along with the Advisory Panel’s vote, which the FDA will consider in making its decision, expected by early 2025.”
IceCure CEO, Eyal Shamir
The Advisory Panel will consist of breast surgeons, interventional radiologists, regulatory representatives, and other experts. Comments are available for public view on the FDA website, and the meeting will be livestreamed. The FDA is expected to make a decision on marketing authorization by early 2025.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities